Browse Trials
In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.
Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.
Currently viewing trials
(Last updated: April 15, 2021)
Close
Treatment
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Non-Treatment
Activities
Complementary and Alternative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Screening
Support/Education
Surveys/Interviews/Registries
Close
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
Click here to view online studies and trials that do not require site visits
1
NEAREST SITE: 27 miles
Stanford University School of Medicine
Stanford,CA
VISITS: 1 visit
PHASE: NA
NCT ID: NCT01034033
How Cancer Develops in Women With BRCA1/2 or Other Genetic Mutations
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples Scientific Title
Purpose
To analyze blood samples from women at high risk of developing breast cancer in order to learn more about how cells change over time from normal to cancerous
Who is this for?
Women at high-risk for developing breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> All participants will provide blood samples.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BRCA 1 and BRCA 2 are tumor suppressor genes.</li> <li class="seamTextUnorderedListItem">Inheriting a mutation in the BRCA 1 or BRCA 2 gene increases cancer risk.</li> <li class="seamTextUnorderedListItem">For the cancer to develop, though, the cells will need to first acquire other mutations.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01034033' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://stanfordhealthcare.org/medical-conditions/cancer/hboc/brca-1-and-2.html' target='_blank'>Stanford Health Care: BRCA1 and BRCA2 Genes</a> </li><li class='seamTextUnorderedListItem'><a href='https://brightpink.org' target='_blank'>Bright Pink: Breast and Ovarian Health Organization</a> </li></ul>
2
NEAREST SITE: 666 miles
University of Washington Medical Center
Seattle,WA
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT02993068
Stand up to Cancer: Making Genetic Testing Accessible
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) Scientific Title
Purpose
To study four approaches to providing education about genetic risk for cancer.
Who is this for?
Women, age 30 or over, with at least one ovary, a history of breast cancer or considered at high risk for breast cancer, and planning to be tested for a breast cancer-related genetic mutation.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch an online educational video before the testing</li> <li class="seamTextUnorderedListItem">Mail in the saliva collection kit </li> <li class="seamTextUnorderedListItem">Receive an online test results report</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch an online educational video before the genetic testing </li> <li class="seamTextUnorderedListItem">Mail in the saliva collection kit </li> <li class="seamTextUnorderedListItem">Receive an online test results report with telephone genetic counseling</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch an online educational video with telephone genetic counseling before the testing</li> <li class="seamTextUnorderedListItem">Mail in the saliva collection kit </li> <li class="seamTextUnorderedListItem">Receive an online test results report with telephone genetic counseling </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Watch an online educational video with telephone genetic counseling before the testing</li> <li class="seamTextUnorderedListItem">Mail in the saliva collection kit </li> <li class="seamTextUnorderedListItem">Receive an online test results report</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers will see what effects the programs have on a woman's understanding of genetics and quality of life.</li> <li class="seamTextUnorderedListItem">The study is using FDA-approved saliva-testing kits and genetic tests.</li> <li class="seamTextUnorderedListItem">To be eligible for this study, you must meet one of the following: diagnosed with breast cancer at 45 or younger; diagnosed with triple negative (ER-, PR-, HER2-) breast cancer at 60 or younger; have one blood relative with a mutation in BRCA 1, BRCA 2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, or PMS2; have one relative with ovarian cancer; have at least 2 relatives with breast cancer on the same side of the family, one of which is 50 years of age or less; or have one male relative with breast cancer.</li> <li class="seamTextUnorderedListItem">Any woman who tests positive for a genetic mutation will have the ability to speak with a genetic counselor.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02993068' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://magenta.mdanderson.org' target='_blank'>MD Anderson Cancer Center Study Information: MAGENTA</a> </li></ul>
3
NEAREST SITE: 1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays,KS
VISITS: 1 visit
PHASE: NA
NCT ID: NCT02302742
A Registry for People with Triple Negative or ER-Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations
PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT) Scientific Title
Purpose
To learn more about the relationship between genetic mutations and cancer outcomes.
Who is this for?
People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> This is a data collection (registry) study. You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 blood test</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Studies have found a relationship between triple negative breast cancer and inherited BRCA1 and BRCA2 mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PTEN, P53, and PALB2</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>ASCO: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Expressions</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ghr.nlm.nih.gov/condition/breast-cancer' target='_blank'>NIH Genetics Home Reference: Breast Cancer</a> </li></ul>
4
NEAREST SITE: 1509 miles
University of Texas Southwestern Medical Center
Dallas,TX
VISITS: Number of visits unavailable
PHASE: NA
NCT ID: NCT04041128
PARP Inhibitor Before Surgery in Women with Triple Negative Breast Cancer & Inherited BRCA1/2 Mutation
Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer Scientific Title
Purpose
To study the effect that olaparib (Lynparza®) has on breast cancer cells when it is given before surgery.
Who is this for?
Women with stage I, stage II, or stage III triple negative (ER-, PR- and HER2-) breast cancer who have an inherited BRCA 1/2 mutation and who have not received any other breast cancer therapies.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice daily, for 7 days before surgery</li> <li class="seamTextUnorderedListItem">1 biopsy</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lynparza is a PARP inhibitor that is approved to treat HER2-negative metastatic breast cancer in women with an inherited BRCA mutation. </li> <li class="seamTextUnorderedListItem">This study is also enrolling women with ovarian cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04041128' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparza.com/breast-cancer/how-lynparza-treats-breast-cancer.html' target='_blank'>AstraZeneca Drug Information Page: Lynparza® (Olaparib)</a> </li></ul>
5
NEAREST SITE: 2561 miles
Memorial Sloan Kettering Bergen
Montvale,NJ
VISITS: Number of visits unavailable, over 2 years
PHASE: NA
NCT ID: NCT00579488
Identifying Different Types of BRCA1 and BRCA2 Mutations
Clinical Significance of Germline BRCA Mutations Scientific Title
Purpose
To identify the range of BRCA mutations found in people who have genetic testing, to better understand the different types of BRCA1 and BRCA2 mutations that increase cancer risk.
Who is this for?
People, including those without breast cancer, who are planning to have a genetic counseling consultation at Memorial Sloan-Kettering Cancer Center in New York City.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> All participants will undergo blood tests</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People who inherit a mutation in the genes known as BRCA1 and BRCA2 are at increased risk of developing breast cancer. </li> <li class="seamTextUnorderedListItem">To be eligible, participants must have a genetic counseling consultation at Memorial Sloan-Kettering Cancer Center in New York City.</li> </ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00579488' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/all-about-cancer/genetics/genetics-breast-cancer' target='_blank'>Cancer.Net: Genetics of Breast Cancer</a> </li></ul>
6
NEAREST SITE: 2693 miles
Dana-Farber Cancer Institute
Boston,MA
VISITS: 1 visit every 3 weeks, for 4.5 months before surgery
PHASE: II
NCT ID: NCT04584255
PARP Inhibitor & Experimental Immunotherapy Before Surgery for Stage I-III, HER2- Breast Cancer with an Inherited BRCA1/2 Mutation
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer Scientific Title
Purpose
To study the safety and anti-cancer activity of giving the experimental PARP inhibitor niraparib (Zejula®) in combination with the experimental PD-1 inhibitor TSR042 (dostarlimab).
Who is this for?
People with stage I, stage II or stage III, HER2 negative (HER2-) breast cancer with a tumor at least 1.5 cm and an inherited BRCA1/2 mutation who have not yet had surgery.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive the following for 4.5 months before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®), by mouth, daily</li> <li class="seamTextUnorderedListItem">TSR042 (Dostarlimab), by IV, every 3 weeks</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®) is a type of targeted therapy called a PARP inhibitor. It is approved for ovarian cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">PARP inhibitors work by blocking the enzyme poly (ADP-ribose) polymerase--this enzyme helps cancer cells grow by repairing their DNA. </li> <li class="seamTextUnorderedListItem">TSR042 (dostarlimab) is an experimental type of immunotherapy called a PD-1 inhibitor. </li> <li class="seamTextUnorderedListItem">Blocking PD-1 allows the body's immune system to detect and fight cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04584255' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/niraparib.aspx' target='_blank'>Chemocare.com: Niraparib (Zejula®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/tsr-042/' target='_blank'>Immuno-Oncology News: TSR-042 (Dostarlimab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zejula.com/en/hcp?cc=ps_2YZEQ6MXT1779794&mcm=220010&gclid=CjwKCAiA6aSABhApEiwA6Cbm_0dmoMN1fy65sxQRaJ4tJP5pyrjG7Zxa2N3W9SHd9XoaJLkymSF0NhoCy6EQAvD_BwE' target='_blank'>GSK Drug Information Page: Zejula® (Niraparib)</a> </li></ul>
7
BRCA Gene Mutations in Latinas and Hispanic Women with Breast Cancer
BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects Scientific Title
Purpose
To study how common BRCA1 and BRCA2 mutations are among Hispanic women and Latinas with breast cancer.
Who is this for?
Women with stage I, stage II, stage III or metastatic (stage IV) breast cancer who are Hispanic or Latina.
Full eligibility criteria
Contact research site
Share with my doctor
Share with my patient
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> All participants will: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide a saliva sample </li> <li class="seamTextUnorderedListItem">Complete a questionnaire </li> <li class="seamTextUnorderedListItem">Provide a copy of pathology report</li> </ul> <p class="seamTextPara"> No study visits are required. The consent process can be done by phone (in English or Spanish) and the questionnaire and saliva collections completed by U.S. mail.</p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some women who have triple negative (ER-, PR-, HER2-) breast cancer also have a BRCA 1 or BRCA 2 genetic mutation.</li> <li class="seamTextUnorderedListItem">The number of Hispanic women and Latinas with triple negative breast cancer who also have a BRCA1/2 mutation is unknown. </li> <li class="seamTextUnorderedListItem">Learning more about BRCA1/2 mutation rates among Latinas and Hispanic women will help researchers provide better treatment.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01251900' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA' target='_blank'>NCI: BRCA Mutations</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Gene Mutations</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html' target='_blank'>Susan G. Komen: Triple Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/espanol/tipos/seno' target='_blank'>NCI: Cá¡ncer de seno</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/espanol/cancer/cancerdeseno/' target='_blank'>American Cancer Society: Cá¡ncer de seno</a> </li></ul>
